Pneumococcal Conjugate Vaccine: How Does It Work?

The pneumococcal conjugate vaccine (PCV) is a type of pneumococcal vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). The pneumococcal vaccine is recommended for babies, older people, and people at higher risk of getting seriously ill from pneumococcal infections. It helps protect against the most common and serious types of these infections, including pneumonia, meningitis, sepsis, sinusitis, and ear infections. The number at the end of each vaccine's name indicates how many types of pneumococcal bacteria it protects against, with newer vaccines like PCV15, PCV20, and PCV21 offering protection against more serotypes.

Explore related products

PNEUMOCOCCAL VACCINE: How To Protect Yourself From Pneumococcal Disease

$9.99

Bioconjugated Materials Part 2 - Applications in Drug delivery, Vaccine formulations and Important conjugates for cancer therapy (Volume 103) (Comprehensive Analytical Chemistry, Volume 103)

$255 $255

New Generation Vaccines

$99.75 $105

Nonclinical Development of Biologics, Vaccines and Specialty Biologics

$124.69 $175

New Vaccine Technologies (Biotechnology Intelligence Unit)

$250

Synthetic Vaccines (Advances in Immunology Book 114)

$137.51 $188

The pneumococcal conjugate vaccine is made with the conjugate vaccine method

The pneumococcal conjugate vaccine is designed to protect infants, young children, and adults against pneumococcal infections caused by specific serotypes or strains of the bacterium. The number at the end of the vaccine name, such as PCV15 or PCV20, indicates how many types of pneumococcal bacteria it protects against. For example, PCV15 protects against 15 different types. The specific serotypes included in each vaccine vary, targeting the most prevalent strains causing pneumococcal disease.

The pneumococcal conjugate vaccine formulation has shown a high probability of protection against the constituent strains. For instance, the Prevnar vaccines link bacterial cell capsule sugars, a feature of these pathogens, to CRM197, a nontoxic variant of diphtheria toxin. This conjugation process enhances the immune response, and the addition of aluminum as an adjuvant further boosts this response. The result is a more robust immune reaction in most healthy individuals.

The pneumococcal conjugate vaccine is one of the pneumococcal vaccine types available, alongside the pneumococcal polysaccharide vaccine. The choice between the two depends on age, medical condition, and previous vaccinations. While the pneumococcal conjugate vaccine is typically given to children and infants, the pneumococcal polysaccharide vaccine is often administered to adults. It's important to consult a healthcare provider to determine the most suitable vaccine for one's specific needs and circumstances.

The pneumococcal conjugate vaccine has been proven effective in preventing severe disease, hospitalization, and even death. It is generally safe, but like all medicines, it can cause side effects. Common side effects in children include decreased appetite, fever, irritability, reactions at the injection site, sleep-related issues, and muscle aches. In adults, additional side effects such as headaches, diarrhea, vomiting, rash, joint pain, and chills may occur. Overall, the pneumococcal conjugate vaccine is a valuable tool in protecting against pneumococcal infections and their potentially severe consequences.

Explore related products

Practical Aspects of Vaccine Development

$190 $200

Nanoparticulate Vaccine Delivery Systems

$121.6 $160

Immunization and States: The Politics of Making Vaccines

$42.55 $55.99

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

$142.5 $200

Visceral Leishmaniasis: Therapeutics and Vaccines (Developments in Immunology)

$166.25 $175

RNA Delivery Function for Anticancer Therapeutics (Nanotechnology for Drugs, Vaccines and Smart Delivery Systems)

$85.49 $89.99

It protects infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae

Pneumococcal disease is caused by bacteria that commonly live in the nose and throat and can cause mild infections, such as ear infections, and more serious infections, including pneumonia, blood infections, and bacterial meningitis.

The pneumococcal conjugate vaccine (PCV) is a type of pneumococcal vaccine that helps to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It does this by containing purified capsular polysaccharides from pneumococcal serotypes, which are individually conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine (PPSV). The number at the end of each vaccine's name indicates how many types of serotypes it protects against. For example, PCV15 protects against 15 types, PCV20 protects against 20 types, and so on.

The World Health Organization (WHO) recommends the use of the pneumococcal conjugate vaccine in routine immunizations given to children. This is because pneumococcal disease is common in young children, although older adults are at the greatest risk of serious illness and death. The vaccine is also recommended for children under the age of two and for unvaccinated children between 24 and 59 months old who are at high risk of pneumococcal infections.

The pneumococcal conjugate vaccine is effective in preventing IPD caused by serotypes in the vaccine. For example, PCV7 reduced invasive disease caused by vaccine serotypes by 97%. PCV15 has a 98% probability of protection against the constituent strains, which caused 80% of pneumococcal disease in infants in the US.

The World Health Organization (WHO) recommends the use of the pneumococcal conjugate vaccine in routine immunizations given to children

The pneumococcal conjugate vaccine (PCV) is a type of pneumococcal vaccine made with the conjugate vaccine method. It is used to protect infants, young children, and adults against diseases caused by the bacterium Streptococcus pneumoniae (pneumococcus). The World Health Organization (WHO) recommends the use of the pneumococcal conjugate vaccine in routine immunizations given to children. This is because pneumococcal disease is the leading vaccine-preventable cause of death in young children worldwide. In 2008 alone, it killed more than 500,000 children under the age of five, with 90% of these deaths occurring in the developing world.

The pneumococcal conjugate vaccine contains purified capsular polysaccharide from pneumococcal serotypes, conjugated to a carrier protein. This improves antibody response compared to the pneumococcal polysaccharide vaccine. The most common side effects in children are decreased appetite, fever (especially in children aged six weeks to five years), irritability, reactions at the injection site (reddening or hardening of the skin, swelling, pain, or tenderness), sleepiness, and poor-quality sleep.

The number of doses and the type of vaccine depend on the child's age, medical condition, and previous vaccinations. In general, the CDC recommends pneumococcal vaccination for children under five and adults over 50 or those at increased risk of pneumococcal disease. In children, the vaccine is administered in four doses (PCV15 or PCV20), one dose at each of the following ages: the first dose (PCV13) at two months old, the second dose at four months, the third dose at six months, and the fourth dose (PCV13) at 12-15 months. Children under two years of age do not respond adequately to the 23-valent adult vaccine, so a pneumococcal conjugate vaccine is used. While this vaccine only covers seven strains out of more than ninety, these strains cause 80-90% of severe pneumococcal disease cases.

The pneumococcal conjugate vaccine has been shown to be highly effective in preventing severe disease and reducing hospitalization and death. In the United States, one year after its introduction in 2000, investigators found a 69% drop in the rate of invasive pneumococcal disease in children under two. By 2004, all-cause pneumonia admission rates had declined by 39%, and rates of hospitalization for pneumococcal meningitis decreased by 66% in children younger than two.

To accelerate the introduction of pneumococcal conjugate vaccines into low-income countries, the GAVI Alliance (GAVI) funded the Pneumococcal Vaccines Accelerated Development and Introduction Plan (PneumoADIP). As of March 2013, 25 GAVI-eligible and supported countries have introduced the vaccine, with 15 additional GAVI countries planning to do so.

The pneumococcal conjugate vaccine is one of several pneumococcal vaccines

There are several versions of the pneumococcal conjugate vaccine. The first version, Prevnar (PCV7), was produced from the seven most prevalent strains of Streptococcus pneumoniae bacteria in the US. The second version, Prevnar 13 (PCV13), contained thirteen serotypes of pneumococcus. It replaced Prevnar and was approved for use in the European Union in 2009 and the US in 2010. The third version, Prevnar 20 (PCV20), was approved by the FDA in 2023 for the prevention of invasive disease caused by 20 different serotypes of S. pneumoniae. Pneumosil is another pneumococcal conjugate vaccine produced by the Serum Institute of India. It contains ten serotypes and was prequalified by WHO in 2020. Capvaxive (PCV21) is a pneumococcal 21-valent conjugate vaccine manufactured by Merck and approved for medical use in the US in 2024.

Pneumococcal vaccines are recommended for babies, older people, and people at higher risk of getting seriously ill from pneumococcal infections. They help protect against the most common and serious types of pneumococcal infections, including pneumonia, blood infections, meningitis, sinusitis, and ear infections. The number at the end of each vaccine's name indicates how many types of pneumococcal bacteria it protects against. For example, PCV15 protects against 15 types, PCV20 protects against 20 types, and PPSV23 protects against 23 types.

The pneumococcal conjugate vaccine is usually well-tolerated, but some side effects may occur. In children, the most common side effects include decreased appetite, fever, irritability, reactions at the injection site, sleepiness, and poor-quality sleep. In adults, the most common side effects are decreased appetite, headaches, diarrhea, fever, vomiting, rash, reactions at the injection site, joint and muscle pain, chills, and fatigue.

The number at the end of the pneumococcal conjugate vaccine name indicates how many types of pneumococcal bacteria it protects against

Pneumococcal vaccines protect against pneumococcal infections, which can cause serious illnesses such as meningitis, sepsis, sinusitis, and ear infections. The pneumococcal conjugate vaccine (PCV) is one such vaccine, designed to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus).

The pneumococcal conjugate vaccine is produced by conjugating the purified capsular polysaccharide of pneumococcal serotypes to a carrier protein. This process improves antibody response compared to the pneumococcal polysaccharide vaccine. The bacterial cell capsule sugars, characteristic of these pathogens, are linked (conjugated) to CRM197, a nontoxic recombinant variant of diphtheria toxin. This results in a more robust immune response in most healthy individuals.

The pneumococcal conjugate vaccine is effective in preventing severe disease, hospitalization, and death. It is important to note that the vaccine contains only a small piece of the germ and therefore cannot cause pneumococcal disease. However, as with any vaccine, there is a small risk of side effects, such as redness, pain, swelling, fever, headache, muscle aches, and tiredness.

Frequently asked questions